30642737|t|Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial.
30642737|a|BACKGROUND AND AIMS: Combined probiotic and selenium supplementation may improve Alzheimer's disease (AD) by correcting metabolic abnormalities, and attenuating inflammation and oxidative stress. This study aimed to determine the effects of probiotic and selenium co-supplementation on cognitive function and metabolic status among patients with AD. METHODS: This randomized, double-blind, controlled clinical trial was conducted among 79 patients with AD. Patients were randomly assigned to receive either selenium (200 mug/day) plus probiotic containing Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum (2 x 109 CFU/day each) (n = 27), selenium (200 mug/day) (n = 26) or placebo (n = 26) for 12 weeks. RESULTS: Selenium supplementation, compared with the placebo, significantly reduced serum high sensitivity C-reactive protein (hs-CRP) (P < 0.001), insulin (P = 0.001), homeostasis model of assessment-insulin resistance (HOMA-IR) (P = 0.002), LDL-cholesterol (P = 0.04) and total-/HDL-cholesterol ratio (P = 0.004), and significantly increased total glutathione (GSH) (P = 0.001) and the quantitative insulin sensitivity check index (QUICKI) (P = 0.01). Compared with only selenium and placebo, probiotic and selenium co-supplementation resulted in a significant increase in mini-mental state examination score (+1.5 +- 1.3 vs. +0.5 +- 1.2 and -0.2 +- 1.1, respectively, P < 0.001). Probiotic plus selenium intake resulted in a significant reduction in hs-CRP (-1.6 +- 1.4 vs. -0.8 +- 1.0 and +0.1 +- 0.5 mg/L, respectively, P < 0.001), and a significant increase in total antioxidant capacity (+89.4 +- 129.6 vs. +20.0 +- 62.5 and -0.7 +- 27.2 mmol/L, respectively, P = 0.001) and GSH (+122.8 +- 136.5 vs. +102.2 +- 135.2 and +1.5 +- 53.2 mumol/L, respectively, P = 0.001) compared with only selenium and placebo. In addition, subjects who received probiotic plus selenium supplements had significantly lower insulin levels (-2.1 +- 2.5 vs. -1.0 +- 1.3 and +0.7 +- 2.0 muIU/mL, respectively, P < 0.001), HOMA-IR (-0.5 +- 0.6 vs. -0.2 +- 0.3 and +0.1 +- 0.4, respectively, P < 0.001), and higher QUICKI (+0.01 +- 0.01 vs. +0.005 +- 0.007 and -0.002 +- 0.01, respectively, P < 0.006) compared with only selenium and placebo. Additionally, probiotic and selenium co-supplementation resulted in a significant reduction in serum triglycerides (-17.9 +- 26.1 vs. -3.5 +- 33.9 and +0.3 +- 9.3 mg/dL, respectively, P = 0.02), VLDL- (-3.6 +- 5.2 vs. -0.7 +- 6.8 and +0.05 +- 1.8 mg/dL, respectively, P = 0.02), LDL- (-8.8 +- 17.8 vs. -8.1 +- 19.2 and +2.7 +- 19.0 mg/dL, respectively, P = 0.04) and total-/HDL-cholesterol (-0.3 +- 0.7 vs. -0.4 +- 0.9 and +0.3 +- 0.6, respectively, P = 0.005) compared with only selenium and placebo. CONCLUSIONS: Overall, we found that probiotic and selenium co-supplementation for 12 weeks to patients with AD improved cognitive function and some metabolic profiles. This study was registered in the Iranian website (www.irct.ir) for registration of clinical trials (http://www.irct.ir: IRCT20170612034497N5).
30642737	14	22	selenium	Chemical	MESH:D012643
30642737	104	123	Alzheimer's disease	Disease	MESH:D000544
30642737	215	223	selenium	Chemical	MESH:D012643
30642737	252	271	Alzheimer's disease	Disease	MESH:D000544
30642737	273	275	AD	Disease	MESH:D000544
30642737	291	314	metabolic abnormalities	Disease	MESH:D008659
30642737	332	344	inflammation	Disease	MESH:D007249
30642737	426	434	selenium	Chemical	MESH:D012643
30642737	503	511	patients	Species	9606
30642737	517	519	AD	Disease	MESH:D000544
30642737	610	618	patients	Species	9606
30642737	624	626	AD	Disease	MESH:D000544
30642737	628	636	Patients	Species	9606
30642737	678	686	selenium	Chemical	MESH:D012643
30642737	727	752	Lactobacillus acidophilus	Species	1579
30642737	754	777	Bifidobacterium bifidum	Species	1681
30642737	783	805	Bifidobacterium longum	Species	216816
30642737	839	847	selenium	Chemical	MESH:D012643
30642737	914	922	Selenium	Chemical	MESH:D012643
30642737	1012	1030	C-reactive protein	Gene	1401
30642737	1035	1038	CRP	Gene	1401
30642737	1053	1060	insulin	Gene	3630
30642737	1106	1124	insulin resistance	Disease	MESH:D007333
30642737	1255	1266	glutathione	Chemical	MESH:D005978
30642737	1268	1271	GSH	Chemical	MESH:D005978
30642737	1306	1313	insulin	Gene	3630
30642737	1378	1386	selenium	Chemical	MESH:D012643
30642737	1414	1422	selenium	Chemical	MESH:D012643
30642737	1603	1611	selenium	Chemical	MESH:D012643
30642737	1661	1664	CRP	Gene	1401
30642737	1887	1890	GSH	Chemical	MESH:D005978
30642737	1998	2006	selenium	Chemical	MESH:D012643
30642737	2070	2078	selenium	Chemical	MESH:D012643
30642737	2115	2122	insulin	Gene	3630
30642737	2407	2415	selenium	Chemical	MESH:D012643
30642737	2457	2465	selenium	Chemical	MESH:D012643
30642737	2530	2543	triglycerides	Chemical	MESH:D014280
30642737	2909	2917	selenium	Chemical	MESH:D012643
30642737	2981	2989	selenium	Chemical	MESH:D012643
30642737	3025	3033	patients	Species	9606
30642737	3039	3041	AD	Disease	MESH:D000544
30642737	Negative_Correlation	MESH:D012643	1401
30642737	Negative_Correlation	MESH:D012643	MESH:D000544
30642737	Positive_Correlation	MESH:D005978	MESH:D012643
30642737	Negative_Correlation	MESH:D012643	MESH:D007333
30642737	Negative_Correlation	MESH:D012643	3630
30642737	Negative_Correlation	MESH:D012643	MESH:D008659
30642737	Negative_Correlation	MESH:D012643	MESH:D007249

